How God Changes Your Brain - Andrew Newberg, M. D_ [139]
Finucane A, Mercer SW. An exploratory mixed methods study of the acceptability and effectiveness of Mindfulness-Based Cognitive Therapy for patients with active depression and anxiety in primary care. BMC Psychiatry. 2006 Apr 7;6:14. PMID.
Grossman P, Niemann L, Schmidt S, Walach H. Mindfulness-based stress reduction and health benefits. A meta-analysis.J Psychosom Res. 2004 Jul;57(1):35–43.
32. Streeter CC, Jensen JE, Perlmutter RM, Cabral HJ, Tian H, Terhune DB, Ciraulo DA, Renshaw PF. Yoga Asana sessions increase brain GABA levels: a pilot study. J Altern Complement Med. 2007 May;13(4):419–26.
33. Infante JR, Torres-Avisbal M, Pinel P, Vallejo JA, Peran F, Gonzalez F, Con-treras P, Pacheco C, Roldan A, Latre JM. Catecholamine levels in practitioners of the transcendental meditation technique. Physiol Behav. 2001 Jan;72(1–2):141–6.
34. Between 1969 and 1996 extensive research was conducted on the use of psychedelic drugs and reported in the Journal of Transpersonal Psychology. The overall consensus concluded that fewer and fewer people reported spiritual or psychological insights after 1973, the year that LSD gained popularity as a recreational drug.
35. O'Leary DS, Block RI, Turner BM, Koeppel J, Magnotta VA, Ponto LB, Watkins GL, Hichwa RD, Andreasen NC. Marijuana alters the human cerebellar clock. Neuroreport. 2003 Jun 11;14(8):1145–51.
36. Block RI, O'Leary DS, Hichwa RD, Augustinack JC, Ponto LL, Ghoneim MM, Arndt S, Ehrhardt JC, Hurtig RR, Watkins GL, Hall JA, Nathan PE, Andreasen NC. Cerebellar hypoactivity in frequent marijuana users. Neuroreport. 2000 Mar 20;11(4):749–53.
37. Ghaffar O, Feinstein A. Multiple sclerosis and cannabis. A cognitive and psychiatric study. Neurology. 2008 Feb 13.
D'Souza DC, Braley G, Blaise R, Vendetti M, Oliver S, Pittman B, Ran-ganathan M, Bhakta S, Zimolo Z, Cooper T, Perry E. Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans. Psychopharmacology (Berl). 2008 Jan 29.
Fisk JE, Montgomery C. Real-world memory and executive processes in cannabis users and non-users. J Psychopharmacol. 2008 Jan 21.
Senn R, Keren O, Hefetz A, Sarne Y. Long-term cognitive deficits induced by a single, extremely low dose of tetrahydrocannabinol (THC): Behavioral, pharmacological and biochemical studies in mice. Pharmacol Biochem Behav. 2008 Jan;88(3):230–7.
Solowij N. Cannabis and Cognitive Functioning. Cambridge University Press, 1998.
38. de Sola Llopis S, Miguelez-Pan M, Peña-Casanova J, Poudevida S, Farre M, Pacifici R, Böhm P, Abanades S, García AV, Zuccaro P, de la Torre R. Cognitive performance in recreational ecstasy polydrug users: a two-year follow-up study. J Psychopharmacol. 2008 Jan 21.
Bedi G, Redman J. Ecstasy use and higher-level cognitive functions: weak effects of ecstasy after control for potential confounds. Psychol Med. 2008 Jan 29:1–12.
Schilt T, Win MM, Jager G, Koeter MW, Ramsey NF, Schmand B, van den Brink W. Specific effects of ecstasy and other illicit drugs on cognition in poly-substance users. Psychol Med. 2007 Nov 8;:1–9.
Montgomery C, Fisk JE. Everyday memory deficits in ecstasy-polydrug users. J Psychopharmacol. 2007 Sep;21(7):709–17.
Rodgers J, Buchanan T, Scholey AB, Heffernan TM, Ling J, Parrott AC. Patterns of drug use and the influence of gender on self-reports of memory ability in ecstasy users: a Web-based study. J Psychopharmacol. 2003 Dec;17(4):389–96.
Rodgers J. Cognitive performance amongst recreational users of “ecstasy.” Psychopharmacology (Berl). 2000 Jul;151(1):19–24.
39. Lerner M, Lyvers M. Values and beliefs of psychedelic drug users: a cross-cultural study. J Psychoactive Drugs. 2006 Jun;38(2):143–7.
40. Hartung J, Skorka D. The HIT clinical profile of psychedelic drug users. J Pers Assess. 1980 Jun;44(3):237–45.
41. Vollenweider FX, Leenders KL, Scharfetter C, Maguire